ARTICLE | Finance
The thesis on Thesan
Strategic investors buy into Thesan's focus on novel dermatology assets
March 10, 2014 7:00 AM UTC
Investors in Thesan Pharmaceuticals Inc.'s $49 million series B round said they were enticed by the dermatology play's desire to pursue novel compounds rather than reformulate or repurpose existing drugs.
Existing investor Novo Ventures led the round, which closed late last month. New investors SV Life Sciences and Lundbeckfond Ventures, as well as existing investor Novartis Venture Fund, also participated. The investment is Lundbeckfond's first in the dermatology space. The firm's Mette Kirstine Agger joined Thesan's board...